Conversations on Cancer: Religious Literacy and Spiritual Care for Patients and Caregivers

Research shows that spiritual care for cancer patients remains an unmet need. During this discussion, the panel will explore the differences between religion and spirituality and how increasing religious literacy and spiritual care may impact overall patient care. The discussion will focus on the patient and caregiver experience of their spirituality during cancer care and how religious literacy may improve the care they receive and provide. While the patient will remain central to the discussion, this conversation will also address how providing spiritual care also impacts the often-overlooked family and friends who care for cancer patients and the burnout-prone clinicians in today’s healthcare arena, who may or may not consider themselves religious.

FDA Expert Panel on Menopause and Hormone Replacement Therapy for Women
▶︎

FDA Expert Panel on Menopause and Hormone Replacement Therapy for Women

Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers
▶︎

Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers

FDA Direct: No One Think It's a Good Idea for Kids to Consume Petroleum Products
▶︎

FDA Direct: No One Think It's a Good Idea for Kids to Consume Petroleum Products

FDA Webinar: Safety Assessment of Genome Editing in Gene Therapy
▶︎

FDA Webinar: Safety Assessment of Genome Editing in Gene Therapy

Financial Transparency & Efficiency of the Prescription Drug, Biosimilar, & Generic Drug User Fees
▶︎

Financial Transparency & Efficiency of the Prescription Drug, Biosimilar, & Generic Drug User Fees

Cell Therapies and Tissue-Based Products: Generating Scientific Evidence to Facilitate Development
▶︎

Cell Therapies and Tissue-Based Products: Generating Scientific Evidence to Facilitate Development

AGDD 2025 | D2S04 - Nitrosamines: Known Issues and Practical Advice
▶︎

AGDD 2025 | D2S04 - Nitrosamines: Known Issues and Practical Advice

AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products
▶︎

AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products

Office of New Drugs Custom Medical Queries(OCMQs) for Safety Signal Detection in Clinical Trial Data
▶︎

Office of New Drugs Custom Medical Queries(OCMQs) for Safety Signal Detection in Clinical Trial Data

FDA Direct: Who Buys the Spin — Hook, Line and Sinker?
▶︎

FDA Direct: Who Buys the Spin — Hook, Line and Sinker?

FDA Grand Rounds: FDA Menopausal Hormone Therapy (MHT) Labeling: Historical Context & Recent Changes
▶︎

FDA Grand Rounds: FDA Menopausal Hormone Therapy (MHT) Labeling: Historical Context & Recent Changes

AGDD 2025 | D2S05 - Workshop Closing Remarks
▶︎

AGDD 2025 | D2S05 - Workshop Closing Remarks

AGDD 2025 | D1S02 - Novel Bioequivalence Study Design Recommendations
▶︎

AGDD 2025 | D1S02 - Novel Bioequivalence Study Design Recommendations

Office of New Drugs Standard Safety Tables and Figures for New Drug and Biologic Applications
▶︎

Office of New Drugs Standard Safety Tables and Figures for New Drug and Biologic Applications

AGDD 2025 | D2S04 – Session 4: Q&A Discussion Panel
▶︎

AGDD 2025 | D2S04 – Session 4: Q&A Discussion Panel

AGDD 2025 | D1S02 - Session 2: Q&A Discussion Panel
▶︎

AGDD 2025 | D1S02 - Session 2: Q&A Discussion Panel

193rd Vaccines and Related Biological Products Advisory Committee Meeting
▶︎

193rd Vaccines and Related Biological Products Advisory Committee Meeting

AGDD 2025 | D1S03 - Day One Closing Remarks
▶︎

AGDD 2025 | D1S03 - Day One Closing Remarks

Understanding Endpoints in Rare Disease Drug Development
▶︎

Understanding Endpoints in Rare Disease Drug Development

Considerations for Collecting/Using Natural History Data Fit for Use in the Regulatory Setting
▶︎

Considerations for Collecting/Using Natural History Data Fit for Use in the Regulatory Setting